Pharming Group NV
AEX:PHARM
Pharming Group NV
Total Current Liabilities
Pharming Group NV
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharming Group NV
AEX:PHARM
|
Total Current Liabilities
$115.8m
|
CAGR 3-Years
25%
|
CAGR 5-Years
9%
|
CAGR 10-Years
24%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Total Current Liabilities
€33.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
25%
|
CAGR 10-Years
21%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Total Current Liabilities
$62.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
9%
|
|
|
argenx SE
XBRU:ARGX
|
Total Current Liabilities
$1B
|
CAGR 3-Years
51%
|
CAGR 5-Years
26%
|
CAGR 10-Years
60%
|
|
|
Merus NV
NASDAQ:MRUS
|
Total Current Liabilities
$87m
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
29%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Total Current Liabilities
$18m
|
CAGR 3-Years
17%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
See Also
What is Pharming Group NV's Total Current Liabilities?
Total Current Liabilities
115.8m
USD
Based on the financial report for Dec 31, 2025, Pharming Group NV's Total Current Liabilities amounts to 115.8m USD.
What is Pharming Group NV's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
24%
Over the last year, the Total Current Liabilities growth was 56%. The average annual Total Current Liabilities growth rates for Pharming Group NV have been 25% over the past three years , 9% over the past five years , and 24% over the past ten years .
